AC Immune is a leading Swiss-based biopharmaceutical company with three products in clinical trials.  We design, discover and develop therapeutic and diagnostic products to prevent and modify diseases caused by misfolding proteins. AC Immune’s two proprietary technology platforms create antibodies, small molecules and vaccines to address large markets across a broad spectrum of central nervous system indications.
Alzheimer’s disease (AD) is the largest indication addressed by our products but AC Immune’s innovative, highly differentiated and disease-modifying therapies are capable of shifting the paradigm in the treatment of other neurodegenerative diseases such as Down syndrome, Parkinson’s disease, Tauopathies, Glaucoma and Huntington’s. 
AC Immune has a large, diversified and promising pipeline featuring seven therapeutic and two diagnostic products in AD. The most advanced of these is crenezumab, an anti-Abeta antibody that is licensed to Genentech reported encouraging phase II  data in mild patients. Crenezumab was chosen by the US National Institute of Health for use in the first-ever Alzheimer’s disease prevention trial. AC Immune is running AD clinical trials for two vaccines ACI-24 (targeting Abeta) and ACI-35 (targeting pTau), while a pre-clinical anti-pTau antibody is partnered with Genentech. In addition, we have partnered our Tau protein PET tracers for developing AD diagnostics with Piramal Imaging.
Alzheimer’s disease affects 44 million people worldwide and by 2030 this number will rise to 76 million at a cost of care of $408 billion. Alzheimer’s drugs are a $6 billion market today; current therapies have proven to be effective only for a limited period of time and do not significantly delay disease progression. In contrast, AC Immune’s therapies are designed to prevent, modify, delay or stop disease progression.
Since its foundation in 2003, the company has raised 84 million Swiss francs (USD 81 million) from private investors.